An observational study in Recurrent Spontaneous Abortion, sponsored by Aimin Zhao. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-26.
Sponsored by Aimin Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Abortion, Spontaneous with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Abortion, Spontaneous · China.
Among the 15 studies in Abortion, Spontaneous with a site in China, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2022, is one of 12 observational ones, and was the 9th registered.
221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.
Browse Abortion, Spontaneous studies →4 of the 15 studies in Abortion, Spontaneous with a site in China are open now. Recruiting first, the newest first:
The Third Xiangya Hospital of Central South University · Sites in China
Ages 20–40 · Women only
The Third Xiangya Hospital of Central South University · Sites in China
Ages 20–40 · Women only
Fu Xing Hospital, Capital Medical University · Sites in China
Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 344 is above the median of 201 across 98 observational studies indexed under Abortion, Spontaneous.
Median enrollment 236 across the 3 interventional studies, 200 across the 12 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Aimin Zhao is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Aimin Zhao has 2 studies filed under Abortion, Spontaneous — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Abortion, Spontaneous with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this prospective observational study is to learn about the effect of low molecular weight heparin (LMWH) application on bone mineral density (BMD) and on calcium-phosphorus metabolism in patients with recurrent spontaneous abortion (RSA), and to compare the degree of bone loss and changes in blood calcium and phosphorus in RSA patients and in control groups with normal pregnancy. By monitoring ultrasound BMD and serum indicators related to maternal bone formation and Ca-P metabolism, the association mechanism between long-term use of LMWH, maternal Ca-P regulation and bone loss will be constructed, so as to contribute to clinical treatment and lifestyle guidance during pregnancy in RSA patients.
Women who meet the inclusion criteria at the outpatient clinic of Renji Hospital are recruited in this study from November 2022 to December 2023. Basic information of all subjects is recorded, including number of miscarriages, duration of breastfeeding, comorbidities, and intake of nutritional supplements. Subjects' medication use during the study is recorded as well. Subjects will undergo ultrasound BMD at six time points: before and after medication during pregnancy preparation, at 10, 24, 32 weeks of pregnancy, and at 42 days postpartum. Peripheral blood will also be collected at the time points above to measure serum osteocalcin, blood calcium, blood phosphorus, 25(OH) D, thyroid hormone, and parathyroid hormone levels. Subjects will be followed up to 42 days postpartum to observe pregnancy outcomes and health conditions of the newborn.
All women with a need for pregnancy preparation or a confirmed pregnancy who meet the inclusion criteria from November 2022 to December 2023 at the outpatient clinic of Renji Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous use of low molecular weight heparin for more than 3 months during pregnancy preparation and during pregnancy with a history of more than 2 consecutive miscarriages before 28 weeks of gestation
Drug: Low molecular weight heparin
No use of low molecular weight heparin during pregnancy preparation and throughout pregnancy and history of more than 2 consecutive miscarriages before 28 weeks of gestation
Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
Also known as: LMWH
ultrasound BMD before medication during pregnancy preparation
use ultrasound to test heel bone mineral density before medication during pregnancy preparation
Time frame: 4 weeks
ultrasound BMD after medication during pregnancy preparation
use ultrasound to test heel bone mineral density after medication during pregnancy preparation
Time frame: up to 16 weeks
ultrasound BMD at 10th weeks of pregnancy
use ultrasound to test heel bone mineral density at 10th weeks of pregnancy
Time frame: up to 26 weeks
ultrasound BMD at 24th weeks of pregnancy
use ultrasound to test heel bone mineral density at 24th weeks of pregnancy
Time frame: 40 weeks
ultrasound BMD at 32nd weeks of pregnancy
use ultrasound to test heel bone mineral density at 32nd weeks of pregnancy
Time frame: 1 year
ultrasound BMD at postpartum
use ultrasound to test heel bone mineral density at postpartum
Time frame: up to 1 year and 2 months
osteocalcin before medication during pregnancy preparation
use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin before medication during pregnancy preparation
Time frame: 4 weeks
osteocalcin after medication during pregnancy preparation
use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin after medication during pregnancy preparation
Time frame: up to 16 weeks
osteocalcin at 10th weeks of pregnancy
use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at 10th weeks of pregnancy
Time frame: up to 26 weeks
osteocalcin at 24th weeks of pregnancy
use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at 24th weeks of pregnancy
Time frame: 40 weeks
osteocalcin at 32nd weeks of pregnancy
use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at 32nd weeks of pregnancy
Time frame: 1 year
osteocalcin at postpartum
use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at postpartum
Time frame: up to 1 year and 2 months
calcium before medication during pregnancy preparation
use peripheral blood test to detect calcium level before medication during pregnancy preparation
Time frame: 4 weeks
calcium after medication during pregnancy preparation
use peripheral blood test to detect calcium level after medication during pregnancy preparation
Time frame: up to 16 weeks
calcium at 10th weeks of pregnancy
use peripheral blood test to detect calcium level at 10th weeks of pregnancy
Time frame: up to 26 weeks
calcium at 24th weeks of pregnancy
use peripheral blood test to detect calcium level at 24th weeks of pregnancy
Time frame: 40 weeks
calcium at 32nd weeks of pregnancy
use peripheral blood test to detect calcium level at 32nd weeks of pregnancy
Time frame: 1 year
calcium at postpartum
use peripheral blood test to detect calcium level at postpartum
Time frame: up to 1 year and 2 months
PTH before medication during pregnancy preparation
use peripheral blood test to detect parathyroid hormone level before medication during pregnancy preparation
Time frame: 4 weeks
PTH after medication during pregnancy preparation
use peripheral blood test to detect parathyroid hormone level after medication during pregnancy preparation
Time frame: up to 16 weeks
PTH at 10th weeks of pregnancy
use peripheral blood test to detect parathyroid hormone level at 10th weeks of pregnancy
Time frame: up to 26 weeks
PTH at 24th weeks of pregnancy
use peripheral blood test to detect parathyroid hormone level at 24th weeks of pregnancy
Time frame: 40 weeks
PTH at 32nd weeks of pregnancy
use peripheral blood test to detect parathyroid hormone level at 32nd weeks of pregnancy
Time frame: 1 year
PTH at postpartum
use peripheral blood test to detect parathyroid hormone level at postpartum
Time frame: up to 1 year and 2 months
live bitrh
A live baby born after 23 weeks of gestation
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Dec 2023, 13 months after the start.
Of 43 observational studies under Abortion, Spontaneous, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 91. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aimin Zhao